The London Company Income Equity portfolio returned 12.3% year-to-date vs. a 14.4% increase in the Russell 1000 Value Index.

Germany’s Formycon has decided today to prematurely terminate the Phase III trial (Lotus) for its biosimilar candidate FYB206 ...

Israel-based clinical-stage company Purple Biotech today announced it is advancing into a Phase II study with NT219 in ...

Comcast Corporation (NASDAQ:CMCSA) is investing in its new ventures with the recently launched Sports & News TV, a new video package for ... key driver for MRK, with Keytruda performing ...

Both Opdivo and Keytruda are still in the foothills of ... However shareholders have raised questions about the compensation package of Vertex's CEO, Jeffrey Leiden, which topped $28 million ...

MSD’s checkpoint inhibitor Keytruda has been cleared by the FDA for use in newly diagnosed cervical cancer patients with less severe disease, becoming the first anti-PD-1/PD-L1 immunotherapy for ...

Our vision for our lead asset NOX-A12 remains clear: to secure approval for its use in glioblastoma patients through a strategic partnership with a pharmaceutical company, supported by ...

Having a strong preclinical, clinical and regulatory package and a clear development pathway for NOX-A12, we have received interest from over 30 notable clinicians in the US, the UK and Germany to ...

Wilcox, based in Boston, has spent more than 30 years in executive leadership roles in the biotech, life sciences and financial sectors. His career includes positions with Exact Sciences ...

Green Shipping Corridors: The Hurdles Ahead Under current and prospective policies from the IMO, EU, and US, the business case… Veson Nautical Opens Dubai Office Veson Nautical (Veson) opened a ...

"We think it's based on, you know, the overall data package we've been able to generate, and the additional follow on data that we've provided the agency," the CEO continued. So we look forward to ...